Please login to the form below

Not currently logged in
Email:
Password:

Bayer Technology Services models drug transport in the liver

Bayer Technology Services will model the active transport of drugs in the liver as part of QuantPro, an initiative of the German Federal Ministry of Education and Research

Bayer Technology Services (BTS) has said it will be modelling the active transport of drugs in the liver as part of QuantPro (Quantitative analysis for the description of dynamic processes in living systems), an initiative of the German Federal Ministry of Education and Research (BMBF).

The project has funds for three years and has been set up to provide "significant improvements" in predicting the effects of drugs, as they are metabolised by the body. It also seeks to develop concepts and instruments which will contribute to the individualisation of drug therapies.

BTS is working on the project in association with a consortium, including the Germen-based IonGate Biosciences, Cell Culture Service and the University Medical Centre Schleswig-Holstein at the University of Kiel.

Many of the main factors that influence transport within the liver are still unknown, so the central focus of the research initiative is to establish new assays which will enable identification of active transport processes within the liver, as well as further development systems biology computer models for the pharmacokinetics of active ingredients.

This project will use software tools developed by BTS: PK-Sim for physiology-based pharmacokinetics (PBPK) simulation; and MoBI for the simulation of pharmacodynamics on a molecular level.

The study will also focus on inter-individual differences which cause genetic variations in the liver's transporter genes. The consortium will leverage the experience gained in Kiel with the Popgen gene database, as well as BTS's knowledge of its PK-Sim PK-Pop module, which can already simulate the physiological variability of key population groups.

Jeorg Lippert, head of systems biology at BTS, said: "As part of the QuantPro initiative, we have established a top-class consortium. Together, we are investigating one of the areas critical to the success or failure of drug therapies. Our work aims to improve the quality of the predictions which influence both development decisions at the pharmaceutical research stage, and the choice of treatment made by clinicians."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics